Repligen Overview
- Year Founded
-
1981
- Status
-
Public
- Employees
-
2,000
- Stock Symbol
-
RGEN
- Investments
-
18
- Share Price
-
$163.70
- (As of Friday Closing)
Repligen General Information
Description
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Contact Information
Website
www.repligen.comCorporate Office
- 41 Seyon Street, Building 1
- Suite 100
- Waltham, MA 02453
- United States
Corporate Office
- 41 Seyon Street, Building 1
- Suite 100
- Waltham, MA 02453
- United States
Repligen Stock Performance
As of 20-Nov-2026, Repligen’s stock price is $163.70. Its current market cap is $10.5B with 63.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $163.70 | $170.29 | $100.99 - $198.87 | $10.5B | 63.9M | 1.17M | -$0.20 |
Repligen Financials Summary
As of 30-Sep-2026, Repligen has a trailing 12-month revenue of $806M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 10,729,112 | 9,163,922 | 7,952,994 | 9,793,942 |
| Revenue | 805,610 | 738,256 | 634,439 | 632,362 |
| EBITDA | 127,407 | 180,852 | 80,258 | 145,324 |
| Net Income | (11,804) | 48,894 | (25,514) | 35,596 |
| Total Assets | 2,926,408 | 2,949,699 | 2,829,666 | 2,831,185 |
| Total Debt | 692,241 | 689,948 | 686,247 | 711,804 |
Repligen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Repligen Comparisons
Industry
Financing
Details
Repligen Competitors (67)
One of Repligen’s 67 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | ||||
| BioAtla | Formerly VC-backed | San Diego, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Laysan Bio | Private Equity-Backed | Arab, AL |
Repligen Patents
Repligen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136802-A2 | Affinity ligands for purification of herpesvirus vaccine antigens | Pending | 20-Dec-2024 | ||
| WO-2026136802-A3 | Affinity ligands for purification of herpesvirus vaccine antigens | Pending | 20-Dec-2024 | ||
| WO-2026136475-A2 | Equalized tangential flow filtration | Pending | 18-Dec-2024 | ||
| WO-2026136475-A3 | Equalized tangential flow filtration | Pending | 18-Dec-2024 | ||
| WO-2026122755-A1 | Kappa light chain affinity ligands | Pending | 04-Dec-2024 | C07K14/00 |
Repligen Signals
Repligen Investments & Acquisitions (18)
Repligen’s most recent deal was a Merger/Acquisition with Biolife Solutions for . The deal was made on 06-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biolife Solutions | 06-Oct-2026 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| 908 Devices (Bioprocessing Process Analytical Technology Portfolio) | 04-Mar-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Tantti | 02-Dec-2024 | Merger/Acquisition | Biotechnology | ||
| Metenova | 02-Oct-2023 | Merger/Acquisition | Medical Supplies | ||
| FlexBiosys | 17-Apr-2023 | Merger/Acquisition | Industrial Supplies and Parts |
Repligen ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
17.6 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Repligen Exits (1)
Repligen’s most recent exit was on 01-Jul-2021 from Polymem. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Polymem | 01-Jul-2021 | Completed |
|
Repligen Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Tantti | Taoyuan, Taiwan | 2014 | |
| Novozymes Biopharma Sweden | Lund, Sweden | 2011 | |
| Engineered Molding Technology | Clifton Park, NY | 2010 | |
| FlexBiosys | San Jose, CA | 2009 | |
| Metenova | Molndal, Sweden | 2009 |
Repligen FAQs
-
When was Repligen founded?
Repligen was founded in 1981.
-
Where is Repligen headquartered?
Repligen is headquartered in Waltham, MA.
-
What is the size of Repligen?
Repligen has 2,000 total employees.
-
What industry is Repligen in?
Repligen’s primary industry is Biotechnology.
-
Is Repligen a private or public company?
Repligen is a Public company.
-
What is Repligen’s stock symbol?
The ticker symbol for Repligen is RGEN.
-
What is the current stock price of Repligen?
As of 20-Nov-2026 the stock price of Repligen is $163.70.
-
What is the current market cap of Repligen?
The current market capitalization of Repligen is $10.5B.
-
What is Repligen’s current revenue?
The trailing twelve month revenue for Repligen is $806M.
-
Who are Repligen’s competitors?
Agenus, Cytovance Biologics, BioAtla, Merck & Co., and Laysan Bio are some of the 67 competitors of Repligen.
-
What is Repligen’s annual earnings per share (EPS)?
Repligen’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process